Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).

8009Background: Carf plus Len-Dex (KRd) or Cyclo-Dex (KCd) is effective in NDMM. Treatment of high-risk pts is an unmet medical need. Methods: NDMM pts ≤65 yrs were randomized (1:1:1; stratificatio...